Eye on Washington

Article

September days are crisper, and President and Congress have returned from summer vacation. It's time to confront the legislative agenda, pass the 13 appropriation bills that keep the federal government functioning, and bring pending legislation to a conclusion.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Related Content
Q2 2025: A recap of the top headlines and interviews | Image Credit: © Uladzislau - stock.adobe.com.

Q2 2025: A recap of the top headlines and interviews

Morgan Ebert, Managing Editor
July 3rd 2025
Article

View our Q2 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Study: Idiopathic central precocious puberty patients at increased risk for psychiatric disorders | Image Credit: © Dzmitry - © Dzmitry - stock.adobe.com.

Study: Idiopathic central precocious puberty patients at increased risk for psychiatric disorders

Joshua Fitch, Senior Editor
July 2nd 2025
Article

Data from the study suggest caretakers of CPP patients be vigilant for psychiatric symptoms to begin care at an early stage.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA revises labeling on extended-release stimulants for ADHD to include weight loss risk | Image Credit: Contemporary Pediatrics

FDA revises labeling on extended-release stimulants for ADHD to include weight loss risk

Joshua Fitch, Senior Editor
July 1st 2025
Article

The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.

© Contemporary Pediatrics

FDA news in pediatrics: June 2025

Morgan Ebert, Managing Editor
July 1st 2025
Article

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.

© 2025 MJH Life Sciences

All rights reserved.